GT Biopharma Amends Share Purchase Agreement

GT Biopharma ( (GTBP) ) has provided an announcement.

GT Biopharma, Inc. announced a significant amendment to its common shares purchase agreement with investors, increasing the beneficial ownership limitation from 4.99% to 9.99% as of June 10, 2025. Additionally, the company experienced changes in its board of directors with the resignation of Andrew Ritter on June 9, 2025, and the appointment of David C. Mun-Gavin as a non-employee director and chair of the Compensation Committee, effective June 10, 2025.

The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.

Spark’s Take on GTBP Stock

According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.

GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.

To see Spark’s full report on GTBP stock, click here.

More about GT Biopharma

GT Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics for the treatment of cancer and other diseases.

Average Trading Volume: 47,694

Technical Sentiment Signal: Sell

Current Market Cap: $9.57M

Find detailed analytics on GTBP stock on TipRanks’ Stock Analysis page.